Hilliard Lyons Neutral On AmSurg Corporation (AMSG)

Hilliard Lyons is Neutral on AmSurg Corporation

in a research report released today. In a note to clients, Hilliard Lyons writes, "There was little change in AmSurg's operating environment in the third quarter. As in previous quarters, same center revenue declined 2% as same center procedure volume also fell 2%. Higher revenue per procedure mitigated some of the decline. AmSurg experienced soft volumes in discretionary procedures such as screening colonscopies, likely the result of economic weakness in the U.S. Management noted that this softness persists." Shares of AMSG lost $1.14 to $18.23, a loss of 5.9%.